Showing 6271-6280 of 7021 results for "".
- Practical Dermatology® Launches #PDGivesBack to Support Camp Discovery at AAD 2016https://practicaldermatology.com/news/practical-dermatology-launches-pdgivesback-to-support-camp-discovery-at-aad-2016/2458672/Bryn Mawr Communications III’s Practical Dermatology® magazine is inviting attendees at the 74th Annual Meeting of the American Academy of Dermatology (AAD) to give back as part of its new “selfless-selfies” campaign.
- Novel Nanotechnology Delivery System May Offer New Approach to Skin Disease Treatmenthttps://practicaldermatology.com/news/novel-nanotechnology-delivery-system-may-offer-new-approach-to-skin-disease-treatment/2458675/A new nanotechnology-based delivery system may help activate the body's natural defense against free radicals and control a variety of skin conditions, report researchers from The Hebrew University of Jerusalem and Technion -- Israel Institute of Technology. Specifically, applyi
- Pioneer in Laser Development to Give Keynote at ASLMS 2016https://practicaldermatology.com/news/pioneer-in-laser-development-to-give-keynote-at-aslms-2016/2458682/Robert Afzal, PhD, a leading expert in high power fiber laser development, will deliver the keynote address at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), to be held in Boston, Massachusetts March 30 – April 2, 2016. Dr. Afzal wi
- FDA Approves Allergan's Aczone Gel, 7.5% for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-allergans-aczone-gel-75-for-acne-vulgaris/2458681/The FDA approved Allergn’s Aczone (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. Aczone Gel, 7.5% delivers proven efficacy to treat both inflammatory and non-inflammatory acne, with a new concentration of dapsone in just once-a-day
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic
- Good Deal: DS Healthcare Acquires Radiancy, Neovahttps://practicaldermatology.com/news/good-deal-ds-healthcare-acquires-radiancy-neova/2458692/DS Healthcare Group, Inc. will acquire Radiancy, Inc., and Neova® from PhotoMedex, Inc. The board of directors of both companies have voted unanimously in favor o
- Sweet Acne Cure: Kanuka Honey from New Zealand May Eradicate Acnehttps://practicaldermatology.com/news/sweet-acne-cure-kanuka-honey-from-new-zealand-may-eradicate-acne/2458693/Kanuka honey may help out the brakes on acne, new research suggests. In the study of Honevo®, developed by New Zealand pharmaceutical company HoneyLab, twice as many participants had an imp
- Sturge-Weber Foundation to Host Dermatology Roundtablehttps://practicaldermatology.com/news/sturge-weber-foundation-to-host-dermatology-roundtable/2458697/The Sturge-Weber Foundation (SWF) is holding a Dermatology Discussion Roundtable meeting on March 5, 2016, at the Marriott Marquis in Washington, DC. Attendees of the American Academy of Dermatology (AAD) conference are invited to attend this breakfast meeting from 7:30 a.m. to 9:30 a.m. in the J
- Hidradenitis Suppurativa Ups Risk of Adverse CV Eventshttps://practicaldermatology.com/news/hidradenitis-suppurativa-ups-risk-of-adverse-cv-events/2458696/Hidradenitis suppurativa (HS) may increase risk for adverse cardiovascular outcomes, a new study suggests. HS has been associated with cardiovascular risk factors, such as smoking and obesity, but the risk of cardiovascular disease in patients with HS was unknown. The new study
- Cipher's Sitavig Accepted for Review by Health Canadahttps://practicaldermatology.com/news/ciphers-sitavig-accepted-for-review-by-health-canada/2458701/Cipher Pharmaceuticals Inc.’s New Drug Submission for Sitavig has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis in adults. In the United States, Sitavig® is approve